Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Clinical Protocols / standards*
  • Drug Administration Schedule
  • Eligibility Determination / standards*
  • Europe
  • Humans
  • Practice Guidelines as Topic*
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • World Health Organization

Substances

  • Antitubercular Agents